Submission of Financial Results for the Quarter and Year ended on 31st March 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Skybiotech Healthcare Limited (formerly Kapil Cotex Limited) reported standalone profit of Rs 5.96 lakh for FY26, a turnaround from loss of Rs 6.03 lakh in FY25. However, on a consolidated basis, the company posted a net loss of Rs 111.68 lakh for FY26, though this is a significant improvement from the Rs 236.89 lakh loss in FY25. Consolidated revenue from operations was Rs 709.78 lakh (vs Rs 705.18 lakh in FY25), showing marginal 0.65% growth. The subsidiary Skybiotech Life Sciences contributed Rs 733.69 lakh in income but reported a loss of Rs 105.72 lakh. The company invested Rs 948.43 lakh in shares during FY25 (explaining the large cash outflow). Auditors issued unmodified opinions on both standalone and consolidated results.
Standalone results show a return to profitability, but consolidated results remain in loss territory. The large subsidiary loss and negative operating cash flow of Rs 151.58 lakh (consolidated) are concerns for investors. The company name change to Skybiotech Healthcare from Kapil Cotex was completed in November 2025.